Search
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, whi...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsNaringin
go.drugbank.com/drugs/DB16859ExperimentalCategories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigationalPatients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory overproduction of adrenocortico...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesImlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalImlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. The FDA approved imlunestrant on September 25, 2025 as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-muta...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesBenzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigationalBenzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesHydrastine
go.drugbank.com/drugs/DB19354ExperimentalCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 SubstratesEquilenin
go.drugbank.com/drugs/DB03515ExperimentalEquilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigationalTiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3). It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transport...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersRibostamycin
go.drugbank.com/drugs/DB03615ApprovedWithdrawnRibostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.